GlycoMimetics, Inc. announced today plans to present at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting study data of the company’s lead drug candidate, rivipansel sodium (GMI-1070), as well as GMI-1271, another novel glycomimetic drug candidate in the GlycoMimetics pipeline.
Help employers find you! Check out all the jobs and post your resume.
